Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Landy J and Hart AL | Commentary: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis. | 2013 | Aliment. Pharmacol. Ther. | pmid:23336680 |
Hirai F et al. | Letter: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis. | 2013 | Aliment. Pharmacol. Ther. | pmid:23336690 |
Schmidt KJ et al. | Letter: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - authors' reply. | 2013 | Aliment. Pharmacol. Ther. | pmid:23336691 |
Baumgart DC et al. | Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. | 2003 | Aliment. Pharmacol. Ther. | pmid:12755840 |
Yamamoto T et al. | Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study. | 2016 | Aliment. Pharmacol. Ther. | pmid:26762838 |
Ierardi E et al. | Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. | 2001 | Aliment. Pharmacol. Ther. | pmid:11207512 |
Travis S | Review article: saving the colon in severe colitis - the case for medical therapy. | 2006 | Aliment. Pharmacol. Ther. | pmid:16961749 |
Romano C et al. | Oral tacrolimus (FK 506) in refractory paediatric ulcerative colitis. | 2010 | Aliment. Pharmacol. Ther. | pmid:20148798 |
McSharry K et al. | Systematic review: the role of tacrolimus in the management of Crohn's disease. | 2011 | Aliment. Pharmacol. Ther. | pmid:21999607 |
Beckebaum S et al. | Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients. | 2009 | Aliment. Pharmacol. Ther. | pmid:19624550 |
Herrlinger KR et al. | Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. | 2010 | Aliment. Pharmacol. Ther. | pmid:20175769 |
Schwrer H et al. | Pantoprazole and cyclosporine or tacrolimus. | 2001 | Aliment. Pharmacol. Ther. | pmid:11284790 |
Yamamoto T et al. | Letter: which patient profile for tacrolimus in ulcerative colitis? Authors' reply. | 2016 | Aliment. Pharmacol. Ther. | pmid:27137731 |
Laharie D and Poullenot F | Letter: which patient profile for tacrolimus in ulcerative colitis? | 2016 | Aliment. Pharmacol. Ther. | pmid:27137730 |
Lawrance IC and Copeland TS | Rectal tacrolimus in the treatment of resistant ulcerative proctitis. | 2008 | Aliment. Pharmacol. Ther. | pmid:18761706 |
Liberal R et al. | Expert clinical management of autoimmune hepatitis in the real world. | 2017 | Aliment. Pharmacol. Ther. | pmid:28004405 |
Segal JP et al. | Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm. | 2017 | Aliment. Pharmacol. Ther. | pmid:28008631 |
Yamamoto T et al. | Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis--authors' reply. | 2016 | Aliment. Pharmacol. Ther. | pmid:27040167 |
Taylor KM and Sparrow MP | Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis. | 2016 | Aliment. Pharmacol. Ther. | pmid:27040166 |
Nakase H et al. | Cytomegalovirus affects clinical outcome of infliximab in ulcerative colitis refractory to tacrolimus. | 2010 | Aliment. Pharmacol. Ther. | pmid:20636704 |